Tirzepatide, an injection medication already approved by the Food and Drug Administration (FDA) to treat Type 2 diabetes, is likely to receive FDA approval for another indication — weight loss — later this year, according to multiple reports.
The medication from Eli Lilly has the potential to become a “blockbuster” weight-loss drug, according to reports. Yet experts caution that many patients may not be able to afford it.
“Tirzepatide is currently FDA-approved for treating Type 2 diabetes, but it is being fast-tracked through the FDA to receive an indication for the treatment of obesity,” Dr. Fatima Stanford of Boston told Fox News Digital.
OZEMPIC TRENDING AS A WEIGHT LOSS DRUG: HERE’S WHY AND WHAT DOCTORS SAY
Stanford is an obesity medicine specialist and an associate professor of medicine and pediatrics at Harvard Medical School.
She also works in the endocrine division at Massachusetts General Hospital.
Here’s a deeper look at some of the issues around this drug and its potential.
What’s the definition of obesity and overweight?
To diagnose obesity, many health care providers use the Body Mass Index screening tool.
“If your BMI is 25.0 to <30, it falls within the overweight range," according to the Centers for Disease Control and Prevention (CDC).
“If your BMI is 30.0 or higher, it falls within the obesity range.”
RUNNING 1 MILE A DAY IS GAINING POPULARITY ONLINE: HOW IT CAN IMPROVE YOUR HEALTH
Approximately 70% of American adults have obesity or are overweight, the FDA says.
These conditions are associated with several leading causes of death, including heart disease, stroke and diabetes.
How do current weight-loss medications work?
The body normally releases two hormones, GLP-1 (glucagon-like peptide) and GIP (glucose-dependent insulinotropic polypeptide), to stimulate the pancreas to release insulin, according to reports.
A current class of weight-loss medications on the market have been trending on TikTok after users discovered celebrities like Elon Musk and Andy Cohen highlighting their success with them.
They are known as GLP-1 receptor agonists, which work by binding to receptors in the body to stimulate the pancreas to produce insulin. This mimics the effects of what the hormone GLP-1 does in the body, according to the University of Utah health’s website.
Victoza, Ozempic and Trulicity are some of the brand names that are GLP-1 receptor agonists and initially developed for the treatment of diabetes, the website added.
HEALTHY LIVING MEANS STAYING ACTIVE INDOORS DURING THE COLD WEATHER MONTHS
When people start eating, that stimulates the release of insulin for better blood sugar control.
Tirzepatide may be more effective because it binds to two receptors that decrease the sense of hunger — compared to only one receptor for current weight-loss medications.
But while the drugs regulate blood sugar levels, researchers found that the drugs also simultaneously cross the receptors in the brain to signal to people that they’re full, per the University of Utah Health’s website.
This feeling of being full sooner — also known as early satiety — leads people to eat less and potentially to lose a lot of weight.
How does tirzepatide work?
Tirzepatide “is a dual agonist, including a GLP-1 agonist and a GIP, which helps regulate blood sugar and weight,” Dr. Stanford said.
It may be more effective than current weight-loss medications because it binds to two receptors that decrease the sense of hunger, compared to only one receptor, such as those highlighted on social media platforms.
30,>
Read More: Tirzepatide drug fast-tracked for weight loss indication by FDA: What to know